Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
Genotype 4 is the least-studied hepatitis C virus genotype and was considered a difficult to
treat genotype due to the disappointing response of chronic hepatitis C genotype 4 to
conventional interferon monotherapy. Recent reports showed that pegylated interferon and
ribavirin combination therapy markedly increased the SVR rate to 55-70%. The duration of
treatment has not been accurately defined. The main objective of this is to assess the
duration of pegylated interferon ribavirin therapy in chronic hepatitis genotype 4 and assess
the clinical utility of rapid and early virologic response in determining the optimal
duration of peg interferon ribavirin therapy in chronic hepatitis C.
Phase:
Phase 4
Details
Lead Sponsor:
Ain Shams University
Collaborators:
Fulbright International Society for Infectious Diseases Schering-Plough TEMPUS Tempus Labs